Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545897 | 1.00 | ANPEP (0.46) | ANPEPSPHK1SPHK2LTA4HDPP8 | |
| SCHEMBL15962159 | 0.84 | CSNK2A2 (0.43) | ANPEPSPHK1LTA4HS1PR1S1PR3 | |
| SCHEMBL26024378 | 0.81 | SPHK1 (0.51) | SPHK1SPHK2LTA4HS1PR1S1PR3 | |
| SCHEMBL20067638 | 0.81 | SPHK1 (0.49) | ANPEPSPHK1SPHK2LTA4HCA12 | |
| SCHEMBL16847608 | 0.79 | MAPT (0.49) | CA1CA2TGM2 | |
| SCHEMBL19017845 | 0.79 | MAPT (0.49) | CA1CA2TGM2 | |
| SCHEMBL25332972 | 0.78 | SIRT5 (0.40) | — | |
| SCHEMBL31123880 | 0.77 | SIRT5 (0.40) | TGM2 | |
| SCHEMBL18100002 | 0.77 | SIRT2 (0.44) | TGM2 | |
| SCHEMBL24395095 | 0.77 | SPHK1 (0.57) | SPHK1SPHK2LTA4HS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718340-B1 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1718340-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005074901-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | ANPEP 949/4885SPHK1 2956/4885SPHK2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.